Quanterix

The AI engine Fit Assessment

Beta

Quanterix Corporation develops a highly sensitive platform for analyzing individual proteins and small molecules, enhancing clinical diagnostics and drug development. Their technology enables early disease detection and precise treatment methods across various therapeutic areas.

Blurb

Quanterix is a biotechnology company that develops ultrasensitive biomarker detection for healthcare.

HQ Location

Billerica (United States)

Founded

2007

Employees

201 - 500

Total funding raised

$850.30M

Funding Status

Grant, March 29, 2022
Subspaces
  • Biomarker Identification

Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.